This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (251)  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in JAMA  Topic Collections  • Women's Health, Other  • Alert me on articles by topic

Annual Trends and Response to Recent Evidence

Adam L. Hersh, MD, PhD; Marcia L. Stefanick, PhD; Randall S. Stafford, MD, PhD

JAMA. 2004;291:47-53.

Context  Postmenopausal hormone therapy use increased dramatically during the past 2 decades because of a prevailing belief in its health benefits. Recent evidence from randomized trials published in July 2002 demonstrated adverse cardiovascular disease events and other risks with hormone therapy in the form of oral estrogen combined with progestin.

Objective  To describe patterns of hormone therapy use from 1995 until July 2003, including the impact of recent evidence.

Design, Setting, and Population  Two databases were used to describe national trends in hormone therapy use from January 1995 to July 2003. The National Prescription Audit database provided data on the number of hormone therapy prescriptions filled by retail pharmacies and the National Disease and Therapeutic Index database provided data on patient visits to office-based physicians during which hormone therapy was prescribed.

Main Outcome Measures  Annual number of hormone therapy prescriptions and characteristics of visits to physicians during which hormone therapy was prescribed.

Results  Annual hormone therapy prescriptions increased from 58 million in 1995 to 90 million in 1999, representing approximately 15 million women per year, then remained stable through June 2002. Adoption of new oral estrogen/progestin combinations, primarily Prempro, accounted for most of this growth. Obstetrician/gynecologists provided more than 70% of hormone therapy prescriptions, and more than one third of patients were older than 60 years. Following the publication of trial results in July 2002, hormone therapy prescriptions declined in successive months. Relative to January-June 2002, prescriptions from January-June 2003 declined by 66% for Prempro and 33% for Premarin. Small increases were observed in vaginal formulations and in new prescriptions for low-dose Premarin. If prescription rates observed through July 2003 remain stable, a decline to 57 million prescriptions for 2003, similar to the rate in 1995, is projected.

Conclusions  Clinical practice responded rapidly to recent evidence of harms associated with hormone therapy. Since July 2002, many patients have discontinued hormone therapy or are tapering to lower doses.

Author Affiliations: Stanford Prevention Research Center, Program on Prevention Outcomes and Practices, Stanford University School of Medicine, Stanford, Calif.

RELATED ARTICLES

The Complex World of Prescribing Behavior
C. David Naylor
JAMA. 2004;291(1):104-106.
EXTRACT | FULL TEXT  

Impact of Clinical Trial Results on National Trends in -Blocker Prescribing, 1996-2002
Randall S. Stafford, Curt D. Furberg, Stan N. Finkelstein, Iain M. Cockburn, Tseday Alehegn, and Jun Ma
JAMA. 2004;291(1):54-62.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Estradiol replacement enhances sleep deprivation-induced c-Fos immunoreactivity in forebrain arousal regions of ovariectomized rats
Deurveilher et al.
Am. J. Physiol. Regul. Integr. Comp. Physiol. 2008;295:R1328-R1340.
ABSTRACT | FULL TEXT  

Menopausal Hormone Therapy and Breast Cancer Phenotype: Does Dose Matter?
Garwood et al.
Ann. Surg. Oncol. 2008;15:2526-2532.
ABSTRACT | FULL TEXT  

A Lifestyle Approach for Primary Cardiovascular Disease Prevention in Perimenopausal to Early Postmenopausal Women
Pettee et al.
AMERICAN JOURNAL OF LIFESTYLE MEDICINE 2008;2:421-431.
ABSTRACT  

Proportion of Invasive Breast Cancer Attributable to Risk Factors Modifiable after Menopause
Sprague et al.
Am J Epidemiol 2008;168:404-411.
ABSTRACT | FULL TEXT  

Tibolone and the Promise of Ideal Hormone-Replacement Therapy
El-Hajj Fuleihan
NEJM 2008;359:753-755.
FULL TEXT  

Invited Commentary: Postmenopausal Unopposed Estrogen and Breast Cancer Risk in the Women's Health Initiative--Before and Beyond
Linet
Am J Epidemiol 2008;167:1416-1420.
ABSTRACT | FULL TEXT  

Factors Associated with Obstetrician-Gynecologists' Response to the Women's Health Initiative Trial of Combined Hormone Therapy
Power et al.
Med Decis Making 2008;28:411-418.
ABSTRACT  

Hormone therapy and the rise and perhaps fall of US breast cancer incidence rates: critical reflections
Krieger
Int J Epidemiol 2008;37:627-637.
ABSTRACT | FULL TEXT  

Commentary: Hormone therapy and breast cancer incidence: did epidemiologists miss an effect on national trends?
Paul
Int J Epidemiol 2008;37:638-640.
FULL TEXT  

Health Risks and Benefits 3 Years After Stopping Randomized Treatment With Estrogen and Progestin
Heiss et al.
JAMA 2008;299:1036-1045.
ABSTRACT | FULL TEXT  

Hormone Therapy, Dilemmas, Medical Decisions.
Schulkin
J Law Med Ethics 2008;36:73-88.
 

Postmenopausal Hormone Therapy and Lung Cancer Risk in the Cancer Prevention Study II Nutrition Cohort
Rodriguez et al.
Cancer Epidemiol. Biomarkers Prev. 2008;17:655-660.
ABSTRACT | FULL TEXT  

Estrogen Plus Progestin and Breast Cancer Detection by Means of Mammography and Breast Biopsy
Chlebowski et al.
Arch Intern Med 2008;168:370-377.
ABSTRACT | FULL TEXT  

Relationship between Menopausal Hormone Therapy and Risk of Ductal, Lobular, and Ductal-Lobular Breast Carcinomas
Li et al.
Cancer Epidemiol. Biomarkers Prev. 2008;17:43-50.
ABSTRACT | FULL TEXT  

Re: Declines in Invasive Breast Cancer and Use of Postmenopausal Hormone Therapy in a Screening Mammography Population
Robbins and Clarke
JNCI J Natl Cancer Inst 2007;99:1815-1815.
FULL TEXT  

Ovarian Cancer and Menopausal Hormone Therapy: More Data and New Questions
Lacey
Cancer Epidemiol. Biomarkers Prev. 2007;16:2524-2525.
FULL TEXT  

Menopausal Hormone Therapy and Risk of Epithelial Ovarian Cancer
Rossing et al.
Cancer Epidemiol. Biomarkers Prev. 2007;16:2548-2556.
ABSTRACT | FULL TEXT  

A Midpoint Assessment of the American Cancer Society Challenge Goal to Decrease Cancer Incidence by 25% Between 1992 and 2015
Sedjo et al.
CA Cancer J Clin 2007;57:326-340.
ABSTRACT | FULL TEXT  

Declines in Invasive Breast Cancer and Use of Postmenopausal Hormone Therapy in a Screening Mammography Population
Kerlikowske et al.
JNCI J Natl Cancer Inst 2007;99:1335-1339.
ABSTRACT | FULL TEXT  

Shifting Breast Cancer Trends in the United States
Anderson et al.
JCO 2007;25:3923-3929.
ABSTRACT | FULL TEXT  

Regional Changes in Hormone Therapy Use and Breast Cancer Incidence in California From 2001 to 2004
Robbins and Clarke
JCO 2007;25:3437-3439.
ABSTRACT | FULL TEXT  

Possible Increase in Liver Enzymes Secondary to Atorvastatin and Black Cohosh Administration
Patel and Derkits
Journal of Pharmacy Practice 2007;20:341-346.
ABSTRACT  

Breast Cancer Incidence, 1980 2006: Combined Roles of Menopausal Hormone Therapy, Screening Mammography, and Estrogen Receptor Status
Glass et al.
JNCI J Natl Cancer Inst 2007;99:1152-1161.
ABSTRACT | FULL TEXT  

Breast Cancer Trends: A Marriage Between Clinical Trial Evidence and Epidemiology
Berry and Ravdin
JNCI J Natl Cancer Inst 2007;99:1139-1141.
FULL TEXT  

Monitoring the randomized trials of the Women's Health Initiative: the experience of the Data and Safety Monitoring Board
Wittes et al.
Clin Trials 2007;4:218-234.
ABSTRACT  

The Decrease in Breast-Cancer Incidence in 2003 in the United States
Ravdin et al.
NEJM 2007;356:1670-1674.
ABSTRACT | FULL TEXT  

Physical Activity and Colon Cancer Risk among Women in the California Teachers Study
Mai et al.
Cancer Epidemiol. Biomarkers Prev. 2007;16:517-525.
ABSTRACT | FULL TEXT  

Effect of genetic variations in platelet glycoproteins Ib{alpha} and VI on the risk for coronary heart disease events in postmenopausal women taking hormone therapy
Bray et al.
Blood 2007;109:1862-1869.
ABSTRACT | FULL TEXT  

Effect of the Women's Health Initiative Study Publication on Hormone Replacement Therapy Use among Women Who Have Undergone BRCA1/2 Testing
Dorval et al.
Cancer Epidemiol. Biomarkers Prev. 2007;16:157-160.
ABSTRACT | FULL TEXT  

A Randomized Trial of Alternative Medicines for Vasomotor Symptoms of Menopause
Mangione
ANN INTERN MED 2006;145:924-925.
FULL TEXT  

The Relative Strength of C-Reactive Protein and Lipid Levels as Determinants of Ischemic Stroke Compared With Coronary Heart Disease in Women
Everett et al.
J Am Coll Cardiol 2006;48:2235-2242.
ABSTRACT | FULL TEXT  

Failure to Adopt Beneficial Therapies Caused by Bias in Medical Evidence Evaluation.
Aberegg et al.
Med Decis Making 2006;26:575-582.
ABSTRACT  

Effect of Conjugated Equine Estrogens on Oxidative Metabolism in Middle-aged and Elderly Postmenopausal Women.
O'Connell et al.
J Clin Pharmacol 2006;46:1299-1307.
ABSTRACT | FULL TEXT  

Menopausal hormone therapy and ovarian cancer risk in the National Institutes of Health-AARP Diet and Health Study Cohort.
Lacey et al.
JNCI J Natl Cancer Inst 2006;98:1397-1405.
ABSTRACT | FULL TEXT  

Complex Actions of Sex Steroids in Adipose Tissue, the Cardiovascular System, and Brain: Insights from Basic Science and Clinical Studies
Turgeon et al.
Endocr. Rev. 2006;27:575-605.
ABSTRACT | FULL TEXT  

Complementary and alternative therapies for the management of menopause-related symptoms: a systematic evidence review.
Nedrow et al.
Arch Intern Med 2006;166:1453-1465.
ABSTRACT | FULL TEXT  

Evolving Approaches in the Treatment of Menopausal Symptoms.
Liu
Obstet Gynecol 2006;108:4-5.
FULL TEXT  

Changes in u.s. Prescribing patterns of menopausal hormone therapy, 2001-2003.
Hing and Brett
Obstet Gynecol 2006;108:33-40.
ABSTRACT | FULL TEXT  

Cessation of Hormone Replacement Therapy After Reports of Adverse Findings From Randomized Controlled Trials: Evidence From a British Birth Cohort
Mishra et al.
Am. J. Public Health 2006;96:1219-1225.
ABSTRACT | FULL TEXT  

Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology
Authors/Task Force Members et al.
Eur Heart J 2006;27:1341-1381.
FULL TEXT  

How Many "Me-Too" Drugs Are Enough? The Case of Physician Preferences for Specific Statins
Austin et al.
The Annals of Pharmacotherapy 2006;40:1047-1051.
ABSTRACT | FULL TEXT  

Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis.
Nelson et al.
JAMA 2006;295:2057-2071.
ABSTRACT | FULL TEXT  

A prospective study of female hormone use and breast cancer among black women.
Rosenberg et al.
Arch Intern Med 2006;166:760-765.
ABSTRACT | FULL TEXT  

Treatment of Menopausal Symptoms in Family Medicine Settings following the Women's Health Initiative Findings
The Florida Behavioral Health Research Consortium et al.
J Am Board Fam Med 2006;19:122-131.
ABSTRACT | FULL TEXT  

Decision making at the fringe of evidence: take what you can get.
Col
Arch Intern Med 2006;166:389-390.
FULL TEXT  

Esterified estrogen and conjugated equine estrogen and the risk of incident myocardial infarction and stroke.
Lemaitre et al.
Arch Intern Med 2006;166:399-404.
ABSTRACT | FULL TEXT  

Conjugated Equine Estrogens and Coronary Heart Disease: The Women's Health Initiative.
Hsia et al.
Arch Intern Med 2006;166:357-365.
ABSTRACT | FULL TEXT  

Prediction of Pulmonary Embolism in the Emergency Department: The Revised Geneva Score
Le Gal et al.
ANN INTERN MED 2006;144:165-171.
ABSTRACT | FULL TEXT  

Changes in Women's Use of Hormones After the Women's Health Initiative Estrogen and Progestin Trial by Race, Education, and Income
Wei et al.
J Natl Cancer Inst Monogr 2005;2005:106-112.
ABSTRACT | FULL TEXT  

Health System Responses to the Women's Health Initiative Findings on Estrogen and Progestin: Organizational Response
Hartsfield et al.
J Natl Cancer Inst Monogr 2005;2005:113-115.
ABSTRACT | FULL TEXT  

Gynaecological health care utilization and use of sex hormones-the study of Health in Pomerania
Schwarz et al.
Hum Reprod 2005;20:2916-2922.
ABSTRACT | FULL TEXT  

Hormone replacement therapy, cancer, controversies, and women's health: historical, epidemiological, biological, clinical, and advocacy perspectives
Krieger et al.
J. Epidemiol. Community Health 2005;59:740-748.
ABSTRACT | FULL TEXT  

SHOULD WE CONSIDER AN ACCEPTABLE DRINKING LEVEL SPECIFICALLY FOR POSTMENOPAUSAL WOMEN? PRELIMINARY FINDINGS FROM THE POSTMENOPAUSAL HEALTH DISPARITIES STUDY
GAVALER
Alcohol Alcohol 2005;40:469-473.
ABSTRACT | FULL TEXT  

Impact of the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22/Reversal of Atherosclerosis With Aggressive Lipid Lowering Trials on Trends in Intensive Versus Moderate Statin Therapy in Ontario, Canada
Austin and Mamdani
Circulation 2005;112:1296-1300.
ABSTRACT | FULL TEXT  

Symptom Experience After Discontinuing Use of Estrogen Plus Progestin
Ockene et al.
JAMA 2005;294:183-193.
ABSTRACT | FULL TEXT  

Vitamin E and Cardiovascular Health: Does Sex Matter?
Redberg
JAMA 2005;294:107-109.
FULL TEXT  

Endometrial Carcinoma Risks among Menopausal Estrogen plus Progestin and Unopposed Estrogen Users in a Cohort of Postmenopausal Women
Lacey et al.
Cancer Epidemiol. Biomarkers Prev. 2005;14:1724-1731.
ABSTRACT | FULL TEXT  

Over-the-Counter Progesterone Cream Produces Significant Drug Exposure Compared to a Food and Drug Administration-Approved Oral Progesterone Product
Hermann et al.
J Clin Pharmacol 2005;45:614-619.
ABSTRACT | FULL TEXT  

Menopause, micronutrients, and hormone therapy
Wylie-Rosett
Am. J. Clin. Nutr. 2005;81:1223S-1231S.
ABSTRACT | FULL TEXT  

Early Changes in Biochemical Markers of Bone Turnover Are Associated with Long-Term Changes in Bone Mineral Density in Elderly Women on Alendronate, Hormone Replacement Therapy, or Combination Therapy: A Three-Year, Double-Blind, Placebo-Controlled, Randomized Clinical Trial
Greenspan et al.
J. Clin. Endocrinol. Metab. 2005;90:2762-2767.
ABSTRACT | FULL TEXT  

Dietary Iron Positively Influences Bone Mineral Density in Postmenopausal Women on Hormone Replacement Therapy
Maurer et al.
J. Nutr. 2005;135:863-869.
ABSTRACT | FULL TEXT  

Hormone Therapy Prescribing Patterns in the United States
Buist et al.
Obstet Gynecol 2004;104:1042-1050.
ABSTRACT | FULL TEXT  

Promotion and Prescribing of Hormone Therapy After Report of Harm by the Women's Health Initiative
Majumdar et al.
JAMA 2004;292:1983-1988.
ABSTRACT | FULL TEXT  

Phytoestrogens for Treatment of Menopausal Symptoms: A Systematic Review
Krebs et al.
Obstet Gynecol 2004;104:824-836.
ABSTRACT | FULL TEXT  

Hormonal exposures and breast cancer in a sample of women with systemic lupus erythematosus
Bernatsky et al.
Rheumatology (Oxford) 2004;43:1178-1181.
ABSTRACT | FULL TEXT  

National Trends in Osteoporosis Visits and Osteoporosis Treatment, 1988-2003
Stafford et al.
Arch Intern Med 2004;164:1525-1530.
ABSTRACT | FULL TEXT  

The WHI Estrogen-Alone Trial--Do Things Look Any Better?
Hulley and Grady
JAMA 2004;291:1769-1771.
FULL TEXT  

Commonly Used Types of Postmenopausal Estrogen for Treatment of Hot Flashes: Scientific Review
Nelson
JAMA 2004;291:1610-1620.
ABSTRACT | FULL TEXT  

Postmenopausal Estrogen for Treatment of Hot Flashes: Clinical Applications
Nelson
JAMA 2004;291:1621-1625.
ABSTRACT | FULL TEXT  

National use of postmenopausal hormone therapy: annual trends and response to recent evidence
Obstet Gynecol 2004;103:796-796.
FULL TEXT  

Declines in HT Use After the WHI and HERS II
JWatch Women's Health 2004;2004:2-2.
FULL TEXT  

The Complex World of Prescribing Behavior
Naylor
JAMA 2004;291:104-106.
FULL TEXT